Comparative Pharmacokinetics of SHR-8068 and Ipilimumab in Healthy Chinese Men

Phase 1 Completed 124 enrolled The Affiliated Hospital of Qingdao University Suzhou Suncadia Biopharmaceuticals Co., Ltd. · collab

RandomizedParallel-groupTriple-blindOther

Summary

This phase 1 study compared the pharmacokinetics of a single intravenous dose of SHR-8068 injection with ipilimumab (YERVOY®) in healthy Chinese men. Safety and immunogenicity were also evaluated.

Timeline

Start: 2024-01-07
Primary completion: 2024-12-19
Completion: 2024-12-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ipilimumab	Monoclonal antibody	0.3 mg/kg	Intravenous
Subject	SHR-8068	Monoclonal antibody	0.3 mg/kg	Intravenous

Indications

No indication recorded.